News

Big news: A long-awaited approval for an advanced pediatric IBD treatment!

  Big news: A long-awaited approval for an advanced pediatric IBD treatment! The European Medicines Agency (EMA) recently adopted a positive opinion extending the use of Stelara (ustekinumab) for children with Crohn’s disease who weigh at least 40kg. Why is this important? - It marks another step forward in improving treatment options for young people living with IBD. -...

World IBD Day 2025: IBD Has No Borders: Breaking Taboos, Talking About It

We are pleased to share our plans for next year´s World IBD Day 2025! Building on last year’s theme, “IBD Has No Borders,” we will continue our journey into 2025, focusing on: “IBD Has No Borders: Breaking Taboos, Talking About It.”  We are working on a social media campaign to address the taboos surrounding IBD that often prevent open discussions about...

EFCCA Magazine 1/2025

The latest edition of EFCCA Magazine is here, packed with updates on what EFCCA has been working on over the past months, insights from our member associations, and an article by Professor Claudio Fiocchi  providing a fresh look at the future of IBD treatment.  A huge thank you to everyone who contributed to making this issue an engaging and insightful read...

Stay connected: Follow us on Instagram!

We’re excited to announce that EFCCA is now on Instagram! By following our new account and inviting your community to follow too, you’ll be helping us amplify our reach and make our voices stronger.  Follow us today @efcca_ibd for engaging content that keeps you informed, inspired and connected! Let’s strengthen our amazing community and spread the word about IBD...

INTERCEPT: Pioneering the future of Crohn’s disease prevention

INTERCEPT: Pioneering the future of Crohn’s disease prevention EFCCA is partnering in the groundbreaking INTERCEPT project! This multi-million Euro research initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU), marks a significant milestone in the fight against Crohn’s disease. By harnessing the power of predictive biomarkers, the project aims to shift Crohn’s...

EFCCA Talk: "Living with Fibrosis: Challenges, Treatments and Innovations"

Fibrosis in IBD: A Challenge We Can’t Ignore On 6 February 2025, EFCCA brought together top researchers, industry experts and patient advocates for a webinar on intestinal fibrosis in IBD—an issue that too often gets overlooked. This session was part of the FIBROTARGET project (Horizon Europe), which is working to improve the prevention, diagnosis, and treatment of fibrosis and fibrostenosis...

Patients Participation in HTA: Final Report Released

After the great success of our conference on HTA  "Empowering Patient Voices in Health Technology Assessment" at the UEGW last October, EFCCA is delighted to share the final report of the consultation process, which involved stakeholders and experts in two rounds of webinars. The main aim of the initiative is to optimise patient associations' participation in the HTA process and...

EFCCA Conference at ECCO Congress 2025 in Berlin

On 20 February 2025, at the 20th ECCO Congress in Berlin, we hosted our conference: "What do IBD patients find important in their treatment? Results from a global Patient Preference survey." During the session, we presented the final results of our Patient Preference Survey, conducted in partnership with KU Leuven. This research provides valuable insights into the priorities...

EFCCA Talk: IUS - Intestinal Ultrasound, a Promising Alternative to Endoscopy?

On 29 January, we hosted our latest EFCCA Talk "Intestinal Ultrasound (IUS): A Promising Alternative to Endoscopy?" to explore whether intestinal ultrasound (IUS) could be a less invasive alternative to endoscopy for IBD monitoring. During the talk Dr. Kerri Novak, Gastroenterologist at the University of Calgary (Canada), discussed the use of intestinal ultrasound (IUS) in...

New European Research Project “PerPrev-CID”

New European Research Project “PerPrev-CID” Aiming to revolutionise personalised prevention and early treatment in chronic inflammatory diseases (CIDs), the PerPrev-CID project focuses on advancing risk prediction, early detection of disease progression, and innovative preventive approaches in rheumatoid arthritis (RA) and Inflammatory Bowel Disease (IBD). Chronic inflammatory diseases like...